TY - JOUR
T1 - Short-term psychological impact of the BRCA1/2 test result in women with breast cancer according to their perceived probability of genetic predisposition to cancer
AU - Brédart, A.
AU - Kop, J. L.
AU - Depauw, A.
AU - Caron, O.
AU - Sultan, S.
AU - Leblond, D.
AU - Fajac, A.
AU - Buecher, B.
AU - Gauthier-Villars, M.
AU - Noguès, C.
AU - Flahault, C.
AU - Stoppa-Lyonnet, D.
AU - Dolbeault, S.
N1 - Funding Information:
This work was conducted by means of a grant from the Canceropôle Ile-de-France and was partly financed, at Institut Curie, within the designated integrated cancer research site (SiRIC). We acknowledge the help of Claire Guillemeau, Tatiana Kogut-Kubiak, Jean-Louis Van Autreve and Mathilde Warcoin for providing family genealogical trees. We are grateful to all women who accepted to take part in this study and who provided their time to complete the questionnaires.
PY - 2013/3/19
Y1 - 2013/3/19
N2 - Background: The effect of BRCA1/2 gene test result on anxiety, depression, cancer-related thought intrusion or avoidance and perceived control over cancer risk was assessed in breast cancer (BC) patients, according to their perceived probability of genetic predisposition to cancer.Methods:Two hundred and forty-three (89% response rate) women with BC completed questionnaires after an initial genetic counselling visit (T1), of which 180 (66%) completed questionnaires again after receiving the BRCA1/2 results (T2). The discrepancy between women's perceived probability of cancer genetic predisposition at T1 and the geneticist's computed estimates was assessed.Results:In all, 74% of women received a negative uninformative (NU), 11% a positive BRCA1/2 and 15% an unclassified variant (UV) result. On hierarchical regression analysis, in women with a positive BRCA1/2 result (vs NU or UV), a lower perceived probability of cancer genetic predisposition than objective estimates at T1 predicted lower levels of anxiety at T2 (β=-0.28; P<0.01), whereas in women receiving a UV result (vs NU or positive BRCA1/2), a lower perceived probability of cancer genetic predisposition than objective estimates at T1 predicted higher levels of anxiety (β=0.20; P<0.01), depression (β=0.19; P<0.05) and intrusion (β=0.18; P<0.05) at T2.Conclusion:The type of BRCA1/2 test result differently affects distress according to women's perceived probability of genetic predisposition before testing.
AB - Background: The effect of BRCA1/2 gene test result on anxiety, depression, cancer-related thought intrusion or avoidance and perceived control over cancer risk was assessed in breast cancer (BC) patients, according to their perceived probability of genetic predisposition to cancer.Methods:Two hundred and forty-three (89% response rate) women with BC completed questionnaires after an initial genetic counselling visit (T1), of which 180 (66%) completed questionnaires again after receiving the BRCA1/2 results (T2). The discrepancy between women's perceived probability of cancer genetic predisposition at T1 and the geneticist's computed estimates was assessed.Results:In all, 74% of women received a negative uninformative (NU), 11% a positive BRCA1/2 and 15% an unclassified variant (UV) result. On hierarchical regression analysis, in women with a positive BRCA1/2 result (vs NU or UV), a lower perceived probability of cancer genetic predisposition than objective estimates at T1 predicted lower levels of anxiety at T2 (β=-0.28; P<0.01), whereas in women receiving a UV result (vs NU or positive BRCA1/2), a lower perceived probability of cancer genetic predisposition than objective estimates at T1 predicted higher levels of anxiety (β=0.20; P<0.01), depression (β=0.19; P<0.05) and intrusion (β=0.18; P<0.05) at T2.Conclusion:The type of BRCA1/2 test result differently affects distress according to women's perceived probability of genetic predisposition before testing.
KW - BRCA1/2 testing
KW - anxiety
KW - depression
KW - perceived probability of genetic predisposition to cancer
KW - stress reactions
UR - http://www.scopus.com/inward/record.url?scp=84874623183&partnerID=8YFLogxK
U2 - 10.1038/bjc.2012.599
DO - 10.1038/bjc.2012.599
M3 - Article
C2 - 23462725
AN - SCOPUS:84874623183
SN - 0007-0920
VL - 108
SP - 1012
EP - 1020
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 5
ER -